| Product NDC: | 0065-1750 |
| Proprietary Name: | ILEVRO |
| Non Proprietary Name: | nepafenac |
| Active Ingredient(s): | 3 mg/mL & nbsp; nepafenac |
| Administration Route(s): | OPHTHALMIC |
| Dosage Form(s): | SUSPENSION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0065-1750 |
| Labeler Name: | Alcon Laboratories, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA203491 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20121220 |
| Package NDC: | 0065-1750-07 |
| Package Description: | 1 BOTTLE, DROPPER in 1 CARTON (0065-1750-07) > 1.7 mL in 1 BOTTLE, DROPPER |
| NDC Code | 0065-1750-07 |
| Proprietary Name | ILEVRO |
| Package Description | 1 BOTTLE, DROPPER in 1 CARTON (0065-1750-07) > 1.7 mL in 1 BOTTLE, DROPPER |
| Product NDC | 0065-1750 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | nepafenac |
| Dosage Form Name | SUSPENSION |
| Route Name | OPHTHALMIC |
| Start Marketing Date | 20121220 |
| Marketing Category Name | NDA |
| Labeler Name | Alcon Laboratories, Inc. |
| Substance Name | NEPAFENAC |
| Strength Number | 3 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC] |